Literature DB >> 23011841

Regulation of the activities of the mammalian transglutaminase family of enzymes.

Cornelius Klöck1, Chaitan Khosla.   

Abstract

Mammalian transglutaminases catalyze post-translational modifications of glutamine residues on proteins and peptides through transamidation or deamidation reactions. Their catalytic mechanism resembles that of cysteine proteases. In virtually every case, their enzymatic activity is modulated by elaborate strategies including controlled gene expression, allostery, covalent modification, and proteolysis. In this review, we focus on our current knowledge of post-translational regulation of transglutaminase activity by physiological as well as synthetic allosteric agents. Our discussion will primarily focus on transglutaminase 2, but will also compare and contrast its regulation with Factor XIIIa as well as transglutaminases 1 and 3. Potential structure-function relationships of known mutations in human transglutaminases are analyzed.
Copyright © 2012 The Protein Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23011841      PMCID: PMC3575910          DOI: 10.1002/pro.2162

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  85 in total

Review 1.  Blood coagulation factor XIII: structure and function.

Authors:  L Muszbek; V C Yee; Z Hevessy
Journal:  Thromb Res       Date:  1999-06-01       Impact factor: 3.944

2.  Characterization of recombinant mouse epidermal-type transglutaminase (TGase 3): regulation of its activity by proteolysis and guanine nucleotides.

Authors:  K Hitomi; S Kanehiro; K Ikura; M Maki
Journal:  J Biochem       Date:  1999-06       Impact factor: 3.387

3.  Inactive zymogen and highly active proteolytically processed membrane-bound forms of the transglutaminase 1 enzyme in human epidermal keratinocytes.

Authors:  P M Steinert; S I Chung; S Y Kim
Journal:  Biochem Biophys Res Commun       Date:  1996-04-05       Impact factor: 3.575

4.  Transformation of cellular factor XIII into an active zymogen transglutaminase in thrombin-stimulated platelets.

Authors:  L Muszbek; G Haramura; J Polgár
Journal:  Thromb Haemost       Date:  1995-04       Impact factor: 5.249

5.  Structural evidence that the activation peptide is not released upon thrombin cleavage of factor XIII.

Authors:  V C Yee; L C Pedersen; P D Bishop; R E Stenkamp; D C Teller
Journal:  Thromb Res       Date:  1995-06-01       Impact factor: 3.944

6.  Two non-proline cis peptide bonds may be important for factor XIII function.

Authors:  M S Weiss; H J Metzner; R Hilgenfeld
Journal:  FEBS Lett       Date:  1998-02-27       Impact factor: 4.124

7.  Identification of the calcium binding site and a novel ytterbium site in blood coagulation factor XIII by x-ray crystallography.

Authors:  B A Fox; V C Yee; L C Pedersen; I Le Trong; P D Bishop; R E Stenkamp; D C Teller
Journal:  J Biol Chem       Date:  1999-02-19       Impact factor: 5.157

8.  The transglutaminase 1 enzyme is variably acylated by myristate and palmitate during differentiation in epidermal keratinocytes.

Authors:  P M Steinert; S Y Kim; S I Chung; L N Marekov
Journal:  J Biol Chem       Date:  1996-10-18       Impact factor: 5.157

9.  Highly active soluble processed forms of the transglutaminase 1 enzyme in epidermal keratinocytes.

Authors:  S Y Kim; S I Chung; P M Steinert
Journal:  J Biol Chem       Date:  1995-07-28       Impact factor: 5.157

10.  A third human tissue transglutaminase homologue as a result of alternative gene transcripts.

Authors:  B M Fraij; R A Gonzales
Journal:  Biochim Biophys Acta       Date:  1996-04-10
View more
  28 in total

1.  Celiac disease patient IgA antibodies induce endothelial adhesion and cell polarization defects via extracellular transglutaminase 2.

Authors:  Cristina Antonella Nadalutti; Ilma Rita Korponay-Szabo; Katri Kaukinen; Martin Griffin; Markku Mäki; Katri Lindfors
Journal:  Cell Mol Life Sci       Date:  2013-08-28       Impact factor: 9.261

2.  Discovery of potent and specific dihydroisoxazole inhibitors of human transglutaminase 2.

Authors:  Cornelius Klöck; Zachary Herrera; Megan Albertelli; Chaitan Khosla
Journal:  J Med Chem       Date:  2014-10-31       Impact factor: 7.446

3.  Production of soluble and active microbial transglutaminase in Escherichia coli for site-specific antibody drug conjugation.

Authors:  Mathias Rickert; Pavel Strop; Victor Lui; Jody Melton-Witt; Santiago Esteban Farias; Davide Foletti; David Shelton; Jaume Pons; Arvind Rajpal
Journal:  Protein Sci       Date:  2015-12-26       Impact factor: 6.725

4.  Thioredoxin-1 Selectively Activates Transglutaminase 2 in the Extracellular Matrix of the Small Intestine: IMPLICATIONS FOR CELIAC DISEASE.

Authors:  Nicholas M Plugis; Brad A Palanski; Chih-Hisang Weng; Megan Albertelli; Chaitan Khosla
Journal:  J Biol Chem       Date:  2016-12-21       Impact factor: 5.157

5.  Autoregulation of SafA Assembly through Recruitment of a Protein Cross-Linking Enzyme.

Authors:  Catarina G Fernandes; Charles P Moran; Adriano O Henriques
Journal:  J Bacteriol       Date:  2018-06-25       Impact factor: 3.490

6.  Transglutaminase inhibition stimulates hematopoiesis and reduces aggressive behavior of crayfish, Pacifastacus leniusculus.

Authors:  Kingkamon Junkunlo; Kenneth Söderhäll; Irene Söderhäll
Journal:  J Biol Chem       Date:  2018-11-13       Impact factor: 5.157

7.  Cystamine and Disulfiram Inhibit Human Transglutaminase 2 via an Oxidative Mechanism.

Authors:  Brad A Palanski; Chaitan Khosla
Journal:  Biochemistry       Date:  2018-03-28       Impact factor: 3.162

8.  Selective inhibition of extracellular thioredoxin by asymmetric disulfides.

Authors:  Thomas R DiRaimondo; Nicholas M Plugis; Xi Jin; Chaitan Khosla
Journal:  J Med Chem       Date:  2013-01-31       Impact factor: 7.446

Review 9.  Current and emerging therapies for coeliac disease.

Authors:  Laura Kivelä; Alberto Caminero; Daniel A Leffler; Maria Ines Pinto-Sanchez; Jason A Tye-Din; Katri Lindfors
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-11-20       Impact factor: 46.802

10.  Structure-Activity Relationships of Potent, Targeted Covalent Inhibitors That Abolish Both the Transamidation and GTP Binding Activities of Human Tissue Transglutaminase.

Authors:  Abdullah Akbar; Nicole M R McNeil; Marie R Albert; Viviane Ta; Gautam Adhikary; Karine Bourgeois; Richard L Eckert; Jeffrey W Keillor
Journal:  J Med Chem       Date:  2017-09-14       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.